Frontlight ResearchEarly access
Taking people in United StatesPhase 2/3
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Key facts
- Who runs it
- Crinetics Pharmaceuticals Inc.
- Where
- Ann Arbor, Boston, Charlottesville, Chicago, Fort Worth, Los Angeles, Minneapolis, New Brunswick, New York, Philadelphia, and San Francisco, United StatesSee the 11 sitesAlso in 12 other countries, 47 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 153 people, planned
- Started
- 22 Jan 2026
- Expected to end
- Mar 2030
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Atumelnant
- Placebo
- Record updated
- 10 November 2026
Who can take part
- Age
- 1 year to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Part A and B participants are eligible to be included in the study only if all of the following criteria apply:
- Male or female at birth, between 1 to <18 years of chronological age at the time of signing the Informed Consent Form (ICF)
- Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency (21-OHD) based on standard medically accepted criteria such as elevated 17-OHP level, confirmed CYP21A2 genetic testing, positive newborn screening with confirmatory second tier testing, or cosyntropin stimulation
- Participants must have an elevated morning serum A4 level >ULN during Screening obtained prior to morning glucocorticoid (GC) administration
- Participants must be on a stable supraphysiologic GC replacement therapy for at least one month prior to Screening
- Compliance, as judged per Investigator discretion, with GC replacement and mineralocorticoid replacement (if applicable) regimen documented during the Screening Period
- Biochemical euthyroidism as determined by the Investigator; Part C inclusion criteria require participants to complete treatment in either Part A or Part B and in the Investigator's opinion it would benefit the participant to continue in Part C, regardless of age
Who cannot take part
- Participants treated with other GCs within 30 days of Screening
- Stress dose of GC therapy within 2 weeks of start of Screening, defined as any dose above the normal maintenance dose, including but not limited to intravenous (IV) or intramuscular (IM) hydrocortisone
- Participants who have been dosed with an investigational drug (including atumelnant) in any prior clinical study within 60 days or 5 half-lives (whichever is longer) prior to the first dose
- History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ
- Part A and Part B: Individuals in Part A and Part B who meet any of the following criteria will be excluded from participation in this study:
- Diagnosis of any form of CAH other than classic 21-OHD
- Use of growth hormones within 1 week of start of Screening for short acting, or within 6 weeks of start of Screening for long acting
- Use of a corticotropin-releasing factor receptor antagonist within 14 days of Screening
- Abnormal sleep/wake cycles (as determined by the Investigator)
- Female participants who are pregnant or lactating
- Individuals in Part C who do not meet the Part C Inclusion Criteria
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 17 years old?
Where in United States
Also in 12 other countries, 47 sites
- University of MichiganAnn Arbor, United StatesContact: Crinetics Clinical TrialsTaking people
- Boston's Children's HospitalBoston, United StatesContact: Crinetics Clinical TrialsTaking people
- University of Virginia Health SystemCharlottesville, United StatesContact: Crinetics Clinical TrialsTaking people
- Ann and Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Crinetics Clinical TrialsTaking people
- Cook Children's Health Care SystemFort Worth, United StatesContact: Crinetics Clinical TrialsTaking people
- Children's Hospital Los AngelesLos Angeles, United StatesContact: Crinetics Clinical TrialsTaking people
- University of MinnesotaMinneapolis, United StatesContact: Crinetics Clinical TrialsTaking people
- Rutgers, Robert Wood Johnson Medical SchoolNew Brunswick, United StatesContact: Crinetics Clinical TrialsTaking people
- Icahn School of Medicine at Mount Sinai, Mount Sinai HospitalNew York, United StatesContact: Crinetics Clinical TrialsTaking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Crinetics Clinical TrialsTaking people
- UCSF Ron Conway Gateway Medical BuildingSan Francisco, United StatesContact: Crinetics Clinical TrialsTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).
The 4 groups in the trial
- Treatment (Part A)Treatment being tested
Open-label, semi-sequential cohorts.
Treatment: Atumelnant
- Active Treatment (Part B)Treatment being tested
Randomized, Parallel Arms, Double-Blind
Treatment: Atumelnant
- Placebo (Part B)Placebo, for comparison
Randomized, Parallel Arms, Double-Blind
Treatment: Placebo
- Open-Label Treatment (Part C)Treatment being tested
Open-label treatment period for participants entering Part C from Part A and B.
Treatment: Atumelnant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension
- Fit questions
- Built from NCT07159841, who can take part
- Record updated
- 10 November 2026